Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04195932 · ClinicalTrials.gov registry record · NA
Exercise as a Modulator of Immune Risk Factors for Ischemic Heart Disease
A NA study of Heart Diseases, sponsored by East Tennessee State University.
- Completed
- Registry status
- NA
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT04195932: Completed NA study of Heart Diseases, sponsored by East Tennessee State University.
NCT04195932 is a NA study of Heart Diseases that has completed, run by East Tennessee State University. The registered enrollment target is 52 participants, below the 5,532-participant average among 85 other Heart Diseases trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04195932, a NA study of Heart Diseases, has completed, sponsored by East Tennessee State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
A before and after study involving 43 adult subjects at risk of having ischemic heart disease. Subjects underwent 6 months of supervised moderate intensity aerobic and resistive exercise training. Blood samples were obtained at entry and at 6 months for measurement of complement (C3), CRP, blood lipid levels, lymphocyte phenotypes, and for the isolation, culture, and measurement of the spontaneous and phytohemagglutinin-induced secretion of proatherogenic and antiatherogenic cytokines by their peripheral blood mononuclear cells (PBMC).
Primary Outcome
Pre- and post-exercise peripheral blood mononuclear cell (PBMC) preparations are isolated from venous blood, washed three times at 10 degrees C with sterile phosphate buffered saline (pH 7.4, 0.1 M) and suspended at a concentration of 2 million cells/uL in RPMI-1640. Preparations are incubated under 5% CO2 at 37 degrees C for 48 hours with phytohemagglutinin (5 ug/ml). Culture supernatants are rendered cell-free and supernatants assayed for Interleukin (IL)-1α, tumor necrosis factor (TNF)-α, and
Conditions Studied
Interventions
- OTHER Exercise training
Study Locations (1)
Tennessee
- James H. Quillen College of Medicine - Johnson City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 1996-12 |
| Est. Completion | 1998-05 |
| Phase | NA |
What the finished NCT04195932 record still lists
NCT04195932 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 5,532-participant average among 85 other Heart Diseases trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Heart Diseases appearing as the primary indexed condition, and to 1 intervention - of which Exercise training is the first listed.
NCT04195932 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT04195932 about?
NCT04195932 is a clinical study titled "Exercise as a Modulator of Immune Risk Factors for Ischemic Heart Disease". A before and after study involving 43 adult subjects at risk of having ischemic heart disease. Subjects underwent 6 months of supervised moderate intensity aerobic and resistive exercise training. Blood samples were obtained at entry and at 6 months for measurement of complement (C3), CRP, blood lip...
What is the current status of trial NCT04195932?
This trial is currently completed. It is a NA study. The enrollment target is 52 participants. The study started on 1996-12. Estimated completion is 1998-05.
What conditions does trial NCT04195932 study?
This clinical trial studies the following conditions: Heart Diseases.
What interventions are being tested in trial NCT04195932?
The interventions under investigation include: Exercise training (OTHER).
Who is sponsoring clinical trial NCT04195932?
This trial is sponsored by East Tennessee State University, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04195932 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04195932's enrollment target sits among peer trials
52 75th of 85 higher than 11 of 85 other Heart Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Angiography and Electrogram Guided Bachmann Bundle Pacing
RECRUITING · NA
-
Understanding Decentralized Trial Engagement and Clinical Impediments Through Digital Efforts (UDECIDE) Among Unrepresented Groups With Poor Cardiovascular and Cardiometabolic Health
RECRUITING · NA
-
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
RECRUITING · NA
-
The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With at Least Mild FMR
RECRUITING · NA
-
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
RECRUITING · NA
-
Use of Bedside Imaging and Community Health Workers for Early Screening and Referral of Pre-symptomatic Stage B Heart Failure in the Emergency Department
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia